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What is the place of suPAR in renal disease? 
 
Moin Saleem 




Context: Soluble urokinase-type plasminogen activator, suPAR is an inflammatory signal 
with pleiotropic biological effects depending on context and post-translational 
modifications. Recently it has been linked to renal disease in several guises, and a key 
question is whether it is a driver or a marker of renal disease, and if so of which types of 
kidney damage.  
Subject of Review: Circulating SuPAR has been postulated to cause acute proteinuric kidney 
disease, specifically FSGS, though both the animal models and clinical data in the original 
reports have been challenged. More recently suPAR levels are linked to risk of progression 
of CKD, either by directly activating signalling pathways in the podocyte, or as a sensitive 
early biomarker.  
Second Opinion: The evidence for suPAR as a driver of FSGS proteinuria is not yet 
established, and more needs to be done, particularly by measuring different circulating 
suPAR fragments and identifying ‘second hits’, to clarify if any role exists. The evidence for 
suPAR as a sensitive biomarker for CKD progression is currently stronger, and needs further 
independent validation as well as prospective serial suPAR measurements in CKD cohorts. 
Whether it is a surrogate marker for ongoing inflammatory drivers of kidney disease, or has 
direct mechanistic effects in podocytes will depend on further studies, as well as trials of 





Soluble urokinase-type plasminogen activator, suPAR, is a soluble receptor, derived from 
the cell membrane tethered receptor uPAR. uPAR is enzymatically cleaved from cell surfaces 
to become suPAR, and is known to be a circulating biomarker closely linked to inflammation, 
organ damage and immune activation in a variety of different disease states.  
More recently suPAR has been linked to renal disease, first as a potential circulating 
bioactive factor causing focal segmental glomerulosclerosis (FSGS), and then as a predictor 
of rate of progression in prevalent chronic kidney disease (CKD), possibly linked to its 
functional interaction with APOL1.  
In this review, I delineate the biology of suPAR and what is known currently about its role in 
kidney disease, discuss aspects we still need to elucidate, and explore how this intriguing 
molecule could take us forward in renal medicine. 
 
 
Biological function of urokinase and uPAR 
 
uPA (urokinase), and its receptor uPAR 
Urokinase, also known as the urokinase-type plasminogen activator (uPA), is a serine 
protease, synthesised in large amounts in the kidney[1], and present in blood and extracellular 
matrix. Its main substrate plasminogen, is an inactive form of the serine protease plasmin. 
Activation of plasmin by the proteolytic activity of uPA on plasminogen leads to 
thrombolysis or matrix degradation (depending on environment). Thus uPA, apart from its 
thrombolytic properties, is also able to affect cell migration, adhesion and mitosis. In the 
extracellular matrix, uPA binds to its cellular receptor, uPAR. uPAR is a membrane bound 
45-55 kDa protein with three extracellular domains (D1, D2 and D3) linked to a 
glycosylphosphatidylinositol (GPI) anchor in the cell membrane[2]. 
 
At the cell surface, uPAR also interacts with several soluble and membrane proteins other 
than uPA, e.g. vitronectin, integrins, and thrombospondin, indicating important downstream  
cellular functions of this system independent of plasminogen activation[2]. 
. 
The different domains of uPAR are notable. The region linking D1 and D2D3 in uPAR is 
prone to cleavage by several proteases including physiologically relevant enzymes such as 
neutrophil elastase, plasmin, and uPA itself[3]. The amino terminal domain of uPAR (D1) 
contains the main uPA-binding site[4], whereas the next two domains of uPAR (D2D3) bind 
the extracellular matrix protein vitronectin[5]. However, full-size uPAR is required to reach 




Generation of soluble uPAR 
When uPAR is cleaved by proteases from the cell surface (at the GPI anchor), a soluble form 
of uPAR (suPAR) is released[7]. The majority of circulating suPAR is generated by GPI-
anchor cleavage, thought to be catalysed by GPI-specific phospholipase-D (GPI-PLD). More 
recently the transmembrane phospholipase-C GDE3 was shown to be a specific enzyme for 
uPAR cleavage[8]. Other proteases, including cathepsin G and PI-PLC, are known to also 
cleave the GPI-anchor and thus suPAR generated by GPI-anchor cleavage is not only 
regulated by one kind of protease but potentially by a mixture of various proteases. Full-
length suPAR (suPAR D1-3) can be cleaved into another two soluble forms with different 
biologic properties, suPAR D2D3 and suPAR DI [7]. Therefore 3 fragments are possible – D1 
– which is rapidly cleared, and not detected in plasma[9]; D1-3 (full length); and D2D3 
 
 
Systemic functions of suPAR 
It is hypothesized that the production of this active (D2D3) form of suPAR by activated 
neutrophils in sites of acute inflammation contributes to the recruitment of monocytes to 
these sites during an inflammatory response[10]. The function of this cleaved receptor has 
been studied further and it has now been well documented that suPAR D2D3 is a chemotactic 
agent[11, 12]. There seems to be very strong evidence that suPAR D2D3 is mediating a 
chemotactic effect on immunologically active cells, whether it is promoting the immune 
response or merely just a result of an increased activation level of the immune system is still 
not clear. 
In healthy individuals, suPAR levels are quite stable in both blood and urine and suPAR 
levels in urine, adjusted according to urine creatinine, correlates positively and strongly with 
plasma suPAR-levels. Also, circadian suPAR plasma-concentrations (measured 24 hr, 20 min 
intervals) appear to be stable[13]. 
 
 
Local (cellular) actions of uPAR/suPAR 
uPAR appears to be important in promoting cell migration. uPAR is able to move on the cell 
surface[14] and will localize into aggregates on the leading edge of migrating cells[15, 16] 
and can regulate the activation state of integrins[17]. 
suPAR is believed to have inhibiting properties on uPAR dependent adhesion, as it is soluble 
and therefore not able to direct integrin and vitronectin molecules to the focal contacts[9, 18]. 
uPAR has dramatic effects on promotion of cell motility, independent of uPA binding, via an 
interaction with vitronectin, initiating a Rac dependent actin reorganisation[7].  
Importantly, the different fragments of suPAR, and the cell type, affect the direction of 
signalling induced by suPAR. In cells where uPA-uPAR is active, full length suPAR acts to 
down-regulate pro-migratory signalling, probably by competitive displacement of the uPA-
uPAR complex from signalling adaptor proteins[19]. Proteolytic cleavage of suPAR to the 
D2D3 form increases its signalling activity, likely because the cleaved form has similar 
signalling ability to uPA. This could be important in interpreting the effects of suPAR 





A role for suPAR in Renal biology 
 
1. Role in primary proteinuric disease (notably FSGS) 
 
There is good evidence from in vitro and animal models that uPAR binds to and activates b3 
integrin on the podocyte cell surface, leading to changes in podocyte motility and 
proteinuria[20]. The first specific action of the uPAR system on renal glomerular cell 
signalling was the demonstration that uPAR expression on podocytes mediates cell 
migration, via avb3 integrin and Rac1, and mediates lipopolysaccharide (LPS) induced 
proteinuria in mice[20]. Subsequently, the same group demonstrated that circulating suPAR 
activated avb3 integrin on podocytes, causing proteinuria in mouse models. Concomitantly 
they found higher levels of circulating suPAR in a high proportion of patients with focal 
segmental sclerosis (FSGS) compared to other glomerular disease[21].  
Following this landmark report, many groups have attempted to reproduce the clinical 
findings in other cohorts. The evidence has been reviewed elsewhere (e.g. [22], [23]), and 
definitive proof of circulating suPAR as a predictive or ongoing clinical biomarker for FSGS 
remains elusive. The difficulty in assessing suPAR as a biomarker for FSGS has been 
compounded by the confounding effect of suPAR levels being negatively correlated with 
GFR, with FSGS often diagnosed in stages of CKD where GFR is already reduced. 
 
There have also been studies to extend the experimental evidence that suPAR is a causative 
factor. These have not been able to replicate the finding that suPAR causes acute proteinuria 
(see below[24, 25]).  
 
suPAR has also been studied in renal biopsy samples. Wu et al found higher suPAR levels in 
common biopsy-proven kidney diseases, especially in diabetic nephropathy (DN) correlating 
with increasing proteinuria. Upregulated expression of suPAR in renal tissue was noted in 
most of the disease samples. Serum suPAR gradually increased with severity and staging of 
DN. In addition, levels of suPAR were linearly related to eGFR and to the amount of 
proteinuria in patients with various kidney diseases[26]. In this study, after adjusting for age 
and multivariate linear regression of eGFR and proteinuria, the suPAR levels are still 
significantly negatively related to eGFR (r = −0.579, p < 0.001) and positively related to 
proteinuria (r = 0.459, p < 0.001). 
There appears to be a multifactorial relationship between circulating suPAR and renal disease 
in general, with levels elevated by decreasing GFR, inflammation, and also some evidence of 
an independent relationship to proteinuria, albeit not consistently yet shown for any one type 
of glomerular disease.  
 
 
Does high circulating suPAR cause proteinuria? 
 
Mouse models 
The original evidence was demonstrated in the mouse model of LPS proteinuria. 
The study by Wei et al used the uPAR knockout mouse (PLAUR-/-) to reintroduce 
recombinant full length suPAR via tail vein injection, and reported induction of proteinuria 
(in LPS mice)[21]. A suPAR variant D1D2 was also generated in that study (not a naturally 
occurring variant) and expressed in WT mice by electroporation, causing rapid proteinuria 
and histological features suggestive of glomerular scarring. 
 
Similarly, in a follow up paper the authors demonstrated that bone marrow derived cells from 
LPS induced proteinuric mice produce excess suPAR, and when transferred to PLAUR-/- 
mice result in proteinuria[27]. 
 
While the original studies by Wei et al [21] showed that full length suPAR can cause rapid 
proteinuria in PLAUR null mice but not wild-type (WT) mice, attempts to replicate acute 
proteinuria in WT mice have not been so far been successful. Cathelin et al confirmed 
absence of proteinuria following full length suPAR exposure in WT mice over a few 
weeks[24]. This was despite demonstration of suPAR deposition in the kidney. Spinale et al 
used constitutive overexpression of suPAR (full length) in wild-type mice, using a transgenic 
model wherein suPAR is inducibly over-expressed by the liver[25]. Again, this did not result 
in proteinuria 
Full length recombinant suPAR did result in some increase in proteinuria in WT mice 
induced by anti CD40 autoantibodies + recurrent FSGS plasma[28]. Furthermore, Hahm et al 
showed that full length suPAR expression from transgenic adipocytes causes very mild but 
significantly increased proteinuria (around 150mg/g) in mice exposed to high levels of 
suPAR for several months[27]. 
 
This implies that the context of suPAR overexpression is important, and the presence of high 




It has not yet been established whether suPAR in humans directly causes proteinuria. 
The natural human experiment of paroxysmal nocturnal haematuria, PNH, supports the 
concept discussed above, that high suPAR levels alone are not enough to initiate proteinuria. 
Here the defect is in the GPI anchoring region of uPAR, resulting in very high ongoing levels 
of circulating suPAR (up to 8000pg/ml), but not primarily proteinuria[29].  
The renal damage in this disease is caused primarily by unregulated microvascular 
thrombotic events, with eventual cortical infarcts[30]. 
Another related question in human disease, is what is the source of increased circulating 
suPAR? The mouse studies above suggest that a bone marrow sub-population could be 
responsible, though the equivalent bone marrow markers are not present in humans, so the 
findings are difficult to confirm in human disease. There are also interesting data showing 
uPAR is significantly upregulated in a variety of different kidney diseases, including minimal 
change disease (MCD), diabetic nephropathy and IgA nephropathy, in glomeruli and tubules, 
alongside increased suPAR in most of these diseases[26], raising a possibility that some of 





Clinical correlation of suPAR levels in proteinuric kidney disease  
 
The original study by Wei et al [21] demonstrated plasma levels of suPAR significantly 
higher in patients with FSGS (compared to other renal conditions) both pre- and post-
transplantation, with higher levels in recurrence post-transplant, compared to those who 
didn’t recur. The authors defined a level of 3000pg/ml as a cut off that implied a high 
probability of diagnosing FSGS. The problem has been that many subsequent studies, 
amounting to a large cohort of patients, have not replicated this association. Some are 
supportive, others show no correlation at all, testing a variety of renal conditions including 
genetic podocyte disease, and normal controls. The conclusion of several of these studies is 
that elevated suPAR correlates closely with eGFR, though other studies have shown this is 
not the only factor contributing to elevated suPAR in kidney disease.  For example one study 
demonstrates suPAR levels correlate with degree of proteinuria independent of eGFR, though 
not just in FSGS patients[26], and another showed high suPAR correlates with increased 
cardiovascular mortality in CKD patients, above the effects of eGFR loss[31]. 
 
Levels of suPAR in FSGS that are deemed to correlate with proteinuria, are similar to levels 
in the normal population, that don’t have (nephrotic range) proteinuria. The average level in a 
population is quoted at 3400pg/ml (higher than the cut off level in the original Wei et al 
paper[21]), and in an intensive care unit averages 10,000pg/ml 
(www.suparnostic.com/index.php/products/resinterpretation). Therefore, at the levels quoted, 
there should be at the least a second hit in FSGS that results in filtration barrier breakdown. 
This has not to date been investigated in the suPAR literature. Moreover, that ‘hit’ needs to 
be present in the transplant recipient, considering that recurrence is not specific to features of 
the donor kidney, therefore making it difficult to implicate podocyte susceptibility. 
 
 
Effect of distinct suPAR fragments 
 
A significant limitation of the human studies to measure suPAR levels is that the available 
ELISA kits do not differentiate different fragments. Additionally, there are glycosylation 
variants of suPAR that have not been independently studied in renal disease. Thus, if there 
are different biological functions of distinct fragments to drive specific renal pathology, this 
has not yet been sufficiently investigated. 
 
Different ratios of suPAR fragments may relate to different levels of protease activity, some 
proteases cleaving the linker region (resulting in D1 and D2-3), some cleaving the GPI 
anchor (resulting in D1-3). 
 
All of the studies, including the original by Wei et al [21], measure suPAR by commercial 
ELISA, which detects all fragments without being able to distinguish if any fragment 
predominates. This leaves an open question about whether FSGS, or other proteinuric 
conditions, might display distinct patterns of circulating suPAR fragments, which could have 
more specific biological effects. As mentioned above, it has been shown that the D2D3 
fragment has opposing effects on cell migration to the full length D1-3 fragment, in cells with 
uPA/uPAR activity[19]. To date there is no clinical evidence of different fragments 
predominating in FSGS. In theory, it would be very plausible to test for suPAR fragments 
from recurrent FSGS patients on a Western blot, using plasma samples immunoprecipitated 





2. Role of suPAR in progression of chronic disease 
 
 
Could suPAR be worsening fibrosis by decreased fibrin removal? 
 
The fibrinolytic pathway has well recognised anti-fibrotic effects. Fibrin forms within the 
organ due to a leakage of plasma from damaged vasculature and activation of the coagulation 
cascade. The extravascular fibrin is not cleared in a timely fashion because of a marked 
increase in the expression of plasminogen activation inhibitor–1 (PAI-1) relative to 
urokinase-type plasminogen activator [32, 33].  
The uPA/uPAR system is therefore involved in a number of processes that are associated 
with turnover of the extracellular matrix (ECM). Plasmin generates matrix metalloproteases 
(MMPs), initiating chemotaxis and extravasation of inflammatory cells, and also permitting 
penetration of those cells into the tissue. Conversely, the activated fibrinolytic system could 
play a role in preventing fibrosis by diminishing the accumulation of matrix via this induction 
of plasmin and MMPs.  
 
It is also suggested that circulating suPAR can influence activity of uPA by acting as a 
scavenger for uPA in the circulation, acting as a competitive inhibitor of uPAR thereby 
limiting uPA effects on attenuating tissue fibrin deposition. This could only occur for full 
length (D1-D3) suPAR, as the D1 region is needed for uPA binding[34]. Thus, the question 
of suPAR potentially modulating renal fibrosis is a very pertinent one.  
 
This can be seen in animal models and human disease, for example overexpression of uPA in 
lungs of mice protects against pro-fibrotic damage[35], and high suPAR levels are associated 
with slow coronary flow (SCF), where epicardial coronary flow is slow (without obstruction), 




suPAR is proposed as a risk predictor for progression of chronic kidney disease 
 
Following the description of suPAR as a potential FSGS ‘circulating factor’ came the 
publication of a major paper delineating a relationship between suPAR levels at baseline 
assessment, and progression of chronic kidney disease (CKD) [37].  
The patients tested were recruited at the time of cardiac catheterisation, with approximately a 
third having normal eGFR at baseline (enrolment). The higher the level of suPAR at baseline, 
the greater the subsequent decline in eGFR. Those with normal eGFR at baseline had the 
greatest suPAR related decline in eGFR. Thus, initial suPAR level appears to be a sensitive 
predictor of rate of decline of renal function, in this cardiac disease population.  
In order to test whether this correlated with inflammatory markers in the same population, the 
authors went on to examine the relationship between a range of inflammatory markers and 
risk of CKD progression[38], and found only a weak correlation, with suPAR remaining 
independently predictive. 
The authors subsequently examined two European paediatric cohorts with established CKD 
of varying aetiologies and reported a similar pattern of more rapid decline associated with 
higher baseline suPAR levels[39]. Importantly, a later Swedish study reported a significant 
correlation between baseline suPAR levels and longitudinal decline in eGFR, higher 
incidence of chronic kidney disease, and hospitalization due to impaired kidney function in a 
cohort of healthy middle-aged participants[40].  None of these studies to date have reported 
whether suPAR levels remain elevated throughout the course of disease progression, which 
would need to be measured longitudinally. 
There is also some data on suPAR as a potential early biomarker for acute kidney injury 
(AKI), suggesting patients who develop AKI post cardiac surgery have a higher level of 
suPAR pre-operatively[41] 
 
suPAR is linked to APOL1 biology 
 
Following on from this, the same group that first described the association between CKD 
progression and suPAR sought to identify a synergy between suPAR and the established 
APOL1 risk variants for CKD[42]. They looked at the Emory cohort initially described, and a 
second cohort, the African American Study of Kidney Disease and Hypertension (AASK). In 
the first, but not the second cohort, high suPAR levels correlated with the high-risk APOL1 
genotype[43].  
SuPAR levels were a substantial feature of the association between APOL1 genotype and 
subsequent eGFR decline. Higher baseline suPAR levels were associated with a significantly 
greater yearly decline in kidney function in patients with two APOL1 risk alleles than those in 
patients with one or zero alleles  
A biological basis for this observation was presented, where it was elegantly shown that 
suPAR, APOL1 and avb3 integrin interact, but the higher risk G1 and G2 allelelic variants of 
APOL1 interact more strongly with activated avb3 integrin on the cell surface. Thus, a 
mechanism of APOL1 risk variant association with more rapid progression of CKD could be 




Is there a unifying role of suPAR in kidney disease? 
The overall question remains as to whether suPAR is (1) a specific driver of kidney 
(podocyte) damage and causes/exacerbates a variety of pathologies from FSGS to CKD to 
AKI, or (2) whether it is a surrogate biomarker of background systemic pathology, 
particularly inflammation, that is driving renal damage in certain clinical situations. 
From the perspective of (1), there is compelling experimental evidence of a biological effect 
of suPAR on podocyte dynamics, particularly via the activation of the b3 integrin signalling 
pathway, and also modulated by APOL1. Given the clear link between APOL1 genotype and 
CKD progression (both in FSGS and other forms of kidney disease), a theoretical basis for 
increased circulating suPAR exacerbating CKD progression has been elucidated. The next 
step is to take the initial link between baseline suPAR levels and progression and establish 
clinical correlative links between sustained suPAR levels and CKD progression. This would 
be required to support a functional role for suPAR in driving progressive damage. 
 
The field has been confused by conflicting studies on suPAR levels in FSGS and needs 
clarity. The best way to approach this is by optimal stratification of patients according to 
current knowledge, combined with greater clarification of suPAR fragments being measured. 
Stratification should aim to define those patients with known ‘circulating factor disease’ 
according to clinical criteria. This involves identification of patients who definitely do or do 
not have circulating factor disease (CFD) by: (i) diagnosis of monogenic disease by gene 
panel analysis for all known SRNS genes, and a detailed family history (in cases of as yet 
undiscovered genes), and (ii) identification of patients with a definite/very highly likely 
circulating factor disease, i.e. initial steroid sensitivity, and development of post-transplant 
recurrence[44]. With those two categories as the negative and positive standards, other forms 
of FSGS/SRNS can be assessed according to suPAR levels found. For example, in the subset 
of children with primary steroid resistance and negative gene panel/exome testing, we have 
demonstrated the rate of post-transplant recurrence is 50%[45]. Therefore at least 50% of 
children in this category would be predicted to have high suPAR levels pre-transplant, and 
have levels comparable to the positive control group. Interestingly at least one previous study 
has reported high suPAR levels in children with monogenic (non circulating factor) SRNS, 
thereby further complicating interpretation[46]. Ideally all of these studies should also 
include measurement of suPAR fragments (D1-3 and D2-3) to determine if there is a 
differential effect/pattern of either fragment. 
 
For the second possibility, that suPAR is a biomarker or surrogate marker for a systemic 
response, one likely biological function is as an inflammatory modulator. There exists a 
wealth of experimental and observational data demonstrating that suPAR is elevated in 
numerous conditions of systemic inflammation or infection, and associated with prognosis. 
This should therefore not be discounted, even if simply as a potential confounder in situations 
where suPAR could otherwise directly be driving kidney damage.  
SuPAR is a prognostic marker in various non-CKD diseases, including cardiovascular 
disease, where it is strongly linked to inflammation. Therefore, the most important alternative 
mechanism to be excluded for suPAR in CKD is that it is a marker of presence or severity of 
inflammatory disease, which is independently driving the severity of the kidney disease (and 
hence progression). This is supported by a report showing that patients with stage I and II 
CKD secondary to glomerulonephritis had higher suPAR levels according to the severity (on 
biopsy) of their glomerulonephritis[47]. 
Interestingly a recent study in the US million veterans’ cohort associates increased baseline 
monocyte count with risk of progression of CKD[48]. This was a graded correlation, with 
higher levels of monocytes associated with greater rate of decline in renal function, very 
similar to the suPAR correlation. Clearly monocyte count can be a marker of chronic 
inflammation, and therefore strengthens the association between degree of inflammation and 
risk of renal function decline[49]. 
 
There are at least two potential scenarios for suPAR in inflammatory renal disease. Could 
suPAR in the kidney be promoting inflammation, chemotaxis in particular, and directly 
amplifying the underlying inflammatory state. Or is it merely marking the systemic (and 
local) inflammatory response that is a primary driver of certain chronic renal diseases (e.g. 
diabetic nephropathy, lupus nephritis, IgAN). In either scenario it could be part of an 
inflammatory milieu that links cardiovascular disease to proteinuric renal disease. 
 
Nevertheless, as long as the data are consistent in other cohorts, this still renders suPAR a 
valuable prognostic marker of progression, a critically required biomarker for reliably testing 
the effect of interventional new compounds (e.g. antifibrotic agents). 
 
If suPAR is a mechanistic driver of renal damage, either acutely causing proteinuria or 
chronically perhaps via an APOL1 mediated pathway, the clinical confirmation could come 
from removal of suPAR, once this technology is available. The most acute and rapid way of 
testing this hypothesis would be in patients with post-transplant recurrence of FSGS, though 
this does not specifically address the link to CKD. In CKD reduction of suPAR over a long 
period of time would be far more challenging. Alternative strategies would be to inhibit the 
downstream pathways in podocytes, for example inhibition of a5b3 integrin signalling with 
novel compounds such as Cilengitide (a peptide molecule inhibitor of av integrin). 
 
If it is to be postulated that the mechanism of suPAR causing proteinuria in FSGS is common 
with the mechanism linking suPAR to CKD progression, then the common pathway (given 
current knowledge) could be via b3 integrin activation. The anomalies lie in the differences in 
clinical presentation, one being of acute and massive proteinuria, the other being progressive 
fibrotic damage with or without proteinuria. Both have similar levels of suPAR. Clearly other 
modifying pathways would need to be discovered to explain these differences.  
 
 
Conclusion and Author’s Opinion 
 
It is clear that suPAR is not the (sole) circulating factor for FSGS, but potentially a fragment 
is having an effect in a subset of patients, with at least one ‘second hit’ necessary, which has 
not yet been found. This could potentially be a cytokine, as part of an inflammatory 
response[50], but alternatively suPAR could simply be a marker of an underlying 
inflammatory state that is driving subsets of disease by another mechanism. 
 
Overall therefore, the view of suPAR in renal disease can be viewed from the perspective of 
(1) a potential circulating factor in SRNS/FSGS, and (2) a biomarker and/or driver of 
accelerated renal damage in CKD.  
For (1), the majority view is that a role for suPAR as an acute proteinuric factor should be set 
aside, until and unless further clinical evidence is gathered. In many cohorts tested to date, 
most are negative or equivocal at best in supporting a distinct association between suPAR 
levels (as currently measured) and active disease. More evidence is also needed to ascertain if 
distinct suPAR fragments are associated with disease activity, in a more specific and 
reproducible manner.  
For (2) the evidence is building that there is a correlation between suPAR levels and risk of 
progression of CKD. One key question to now ascertain is whether this is a correlative 
biomarker, measuring coincident inflammatory activity in particular, or whether suPAR is a 
mechanistic driver of renal damage. This could be by biological effects on podocyte 
migratory pathways, with key evidence demonstrating an effect on the APOL1/b3 integrin 
signalling axis, or by more general effects as a scavenger for uPA, thereby limiting aspects of 
chronic fibrosis. It may be that a combination of the above factors explains the link seen 
between suPAR and CKD progression 
SuPAR could differentiate between inflammatory and non-inflammatory causes of CKD, and 
this needs more nuanced investigation. Overall this yields suPAR a promising biomarker for 
CKD progression, which needs further validation, particularly by longitudinal measurements 
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